News & Updates

Vaccines provide the best defense against COVID-19, but they are not without limitations. Acute infections still occur in some, especially those who are older, smokers, obese, or with type 2 diabetes (T2D), as reported in a study.

In high-risk nonhospitalized patients with mild-to-moderate COVID-19, intramuscular administration of the monoclonal antibody sotrovimab was noninferior to IV infusion of the drug, according to findings from the phase III COMET-TAIL trial presented at CROI 2022.

While additional tirofiban prior to endovascular treatment (EVT) did not appear to benefit stroke patients with large vessel occlusion (LVO), it did seem to have an advantage for those with large artery atherosclerosis (LAA), findings from the RESCUE BT trial have shown.

CT-P6, a trastuzumab biosimilar approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC), is as efficacious as reference trastuzumab in terms of response rates, progression-free (PFS) and overall survival (OS), a study has shown.

Patients with inflammatory bowel disease (IBD) who have completed a COVID-19 vaccine regimen have a low risk of developing COVID-19, though receipt of mRNA vaccines may offer better protection, according to a small study presented at the Crohn’s and Colitis Congress 2022.

A novel transdermal device for the delivery of triamcinolone demonstrates efficacy comparable to that of conventional topical steroids in the treatment of nail psoriasis, according to a Singapore study.